U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...

MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II ...

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...

For Tammy Gusher Delgado, 56, the decision to join a clinical trial was clear. With a recent multiple sclerosis diagnosis and a clinical trial offering either the study drug or an approved ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...